{"nctId":"NCT00220961","briefTitle":"Actos Now for Prevention of Diabetes (ACT NOW)","startDateStruct":{"date":"2004-01"},"conditions":["Impaired Glucose Tolerance","Type 2 Diabetes"],"count":602,"armGroups":[{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]},{"label":"Pioglitazone","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Pioglitazone"]}],"interventions":[{"name":"Pioglitazone","otherNames":["Actos"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Men and women\n* All ethnic groups\n* 18 years of age and older\n* Impaired glucose tolerance by glucose tolerance test (fasting glucose 95-125 mg/dl and 2 hr glucose of 140-199 mg/dl)\n* At least one of the following:\n\n  * One or more components of the insulin resistance syndrome (HDL \\< 40 mg/dl in females and \\<35 mg/dl in males, fasting triglycerides \\> 150 mg/dl, blood pressure \\> 135/85 mmHg, BMI \\> 24 kg/m2, waist circumference \\> 102 cm in men and \\> 88 cm in women)\n  * One or more first degree relatives with type 2 diabetes\n  * History of gestational diabetes\n  * Polycystic ovarian disease\n  * Minority ethnic background (Mexican American, African American, Asian and Pacific Islanders, Native American)\n\nExclusion Criteria:\n\n* Type 2 diabetes\n* Previously treated with thiazolidinediones (ever) or metformin (within one year)\n* Previously treated with a sulfonylurea, a meglitinide, an alpha glucosidase inhibitor for more than a week within last year or within the 3 months prior to randomization\n* Previously treated with insulin (other than during pregnancy) for more than one week within the last year or within the 3 months prior to randomization\n* Cardiovascular disease\n* Hospitalization for treatment of heart disease or stroke in past 6 months\n* New York Heart Association Functional Class \\> 2\n* Left bundle branch block or third degree AV block\n* Aortic stenosis\n* SBP \\> 180 mmHg or DBP \\> 105 mmHg\n* Renal disease\n* Anemia\n* Hepatitis\n* GI diseases (pancreatitis, inflammatory bowel disease)\n* Recent or significant abdominal surgery\n* Advanced pulmonary disease\n* Chronic infections\n* Weight loss \\> 10% in past 6 months\n* Pregnancy and childbearing\n* Major psychiatric disorders\n* Excessive alcohol intake\n* Thiazide use \\> 25 mg per day\n* Non-selective beta blockers\n* Niacin\n* Systemic glucocorticoids\n* Weight loss or weight gain medication\n* Thyroid disease-suboptimally treated\n* Active endocrine diseases (Cushing's, acromegaly)\n* Plasma triglycerides over 400 mg/dl (despite treatment)\n* History bladder cancer\n* Hematuria","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Prevention of Type 2 Diabetes","description":"Percentage of Participants with Type 2 Diabetes at 2.4 years Post-randomization","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16.1","spread":null},{"groupId":"OG001","value":"5.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Fasting Plasma Glucose of 2.4 Years","description":"Fasting Plasma Glucose","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.0","spread":"0.09"},{"groupId":"OG001","value":"-10.7","spread":"0.9"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Plasma Insulin Concentration During Oral Glucose Tolerance Test","description":"Insulin secretion","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"35","spread":"5"},{"groupId":"OG001","value":"25","spread":"4"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Matsuda Index of Insulin Sensitivity (There Are no Minimum/Maximum Values)","description":"Insulin sensitivity The Matsuda index was calculated as 10,000/square root of (pre-meal glucose x pre-meal insulin x mean 120 min post-meal glucose x mean 120 min post-meal insulin), with higher numbers indicating better the insulin sensitivity.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.7","spread":"0.2"},{"groupId":"OG001","value":"3.6","spread":"0.2"}]}]}]},{"type":"SECONDARY","title":"Change in Atherosclerosis","description":"carotid intima thickness","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.7","spread":"0.2"},{"groupId":"OG001","value":"3.2","spread":"0.2"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":299},"commonTop":["Other","Myocardio infarction, heart failure, other"]}}}